TA-ASSOCIATES
Francisco Partners (“FP”) and TA Associates (“TA”), leading global investment firms, announced today that they have signed an agreement to become co-controlling shareholders of Orisha, a leading European vertical software company based in France. TA, Orisha’s majority shareholder since 2021, will reinvest in the Company alongside Francisco Partners and Orisha management. The investment will allow Orisha to further advance its growth journey, solidifying its industry leadership through ongoing organic growth, diversification, geographic expansion and strategic acquisitions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240716551941/en/
Headquartered in Paris, Orisha, formerly known as DL Software, was established in 2003 to bring industry-specific ERP software to a variety of end markets in France. The Group now employs over 1,800 people and offers highly specialized vertical software solutions to over 40,000 customers. Previously supported by 21 Invest France, which is now a minority investor, Orisha has grown revenue by approximately four times and transformed its operating model since TA’s initial investment in 2021, consolidating more than 25 independent business lines into five vertically focused business units: Retail, Health & Safety, Construction, Real Estate and Agri-Food. These business units are now supported by centralized functional teams for finance, HR and technology infrastructure. With over €250 million of revenue expected this year, Orisha’s strategic objective is to offer high-quality and agile software solutions to customers by maintaining customer proximity, accelerating technological innovation and increasing organizational integration.
Jacques Ollivier, CEO of Orisha said, “We are thrilled to onboard Francisco Partners alongside TA as we aim to drive continued growth and further enhance Orisha’s offerings. Both TA and Francisco Partners share our vision for the Company, and we are excited to work together to ensure sustained strong performance in the future. With their support, Orisha is positioned for expansion and to provide our customers with the best solutions.”
“Since our initial investment three years ago, Orisha has experienced meaningful growth and positive transformation under the direction of Jacques and the entire leadership team. We remain deeply confident in the Company’s long-term organic and inorganic growth potential, and we look forward to collaborating with Francisco Partners for the next chapter of Orisha’s journey,” said Maxime Cancre, Director, and Patrick Sader, Managing Director, at TA.
“We are big believers in the power of vertical software and hence fully aligned with Orisha’s mission and vision to build industry-specific solutions. Having tracked the company closely for years, we have been impressed by all that the Orisha team has accomplished, under the leadership of Jacques. Working in partnership with him and TA, we will seek to support Orisha’s next stage of growth by continuing to serve its loyal customer base and expanding thoughtfully into new segments,” said Quentin Lathuille, Principal, and Petri Oksanen, Partner and Co-Head of European Investing, at Francisco Partners.
J.P. Morgan acted as exclusive financial advisor and Latham and Watkins acted as legal advisor to TA. Bryan Garnier acted as financial advisor and Paul Hastings acted as legal advisor to Francisco Partners.
The transaction remains subject to regulatory and antitrust approvals and is expected to close in Q4 2024. Financial terms of the transaction were not disclosed.
About Orisha
Founded in 2003, Orisha is a European software publisher dedicated to companies in the retail, real estate, healthcare, construction and agri-food sectors. Since its creation, Orisha has been helping companies to succeed by offering them solutions tailored to their business needs and essential to their activity (cash collection, commercial and financial management, stock management, CRM, HR, unified commerce…). Each day, Orisha’s solutions facilitate millions of interactions and transactions in a hyper-connected world. Since 2021, Orisha has been backed by TA Associates, a global private equity player and leader in the technology sector. In 2023, Orisha achieved sales in excess of €200m. The group, which was born in France, employs 1,800 people in Europe and supports clients in over 50 countries. More information: https://www.orisha.com
About Francisco Partners
Francisco Partners is a leading global investment firm that specializes in partnering with technology and technology-enabled businesses. Since its launch 25 years ago, Francisco Partners has invested in more than 450 technology companies, making it one of the most active and longstanding investors in the technology industry. With approximately $45 billion in capital raised, the firm invests in opportunities where its deep sectoral knowledge and operational expertise can help companies realize their full potential. For more information on Francisco Partners, please visit www.franciscopartners.com.
About TA
TA is a leading global private equity firm focused on scaling growth in profitable companies. Since 1968, TA has invested in more than 560 companies across its five target industries – technology, healthcare, financial services, consumer and business services. Leveraging its deep industry expertise and strategic resources, TA collaborates with management teams worldwide to help high-quality companies deliver lasting value. The firm has raised $65 billion in capital to date and has over 150 investment professionals across offices in Boston, Menlo Park, Austin, London, Mumbai and Hong Kong. For more information, visit www.ta.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240716551941/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Illumynt Reports Q3 2025 Business Update17.10.2025 14:39:00 CEST | Press release
Q3 2025 was a busy quarter once again for us here at illumynt. In addition to naming a new CEO, we executed on a number of initiatives that are propelling our organization forward. Revenue for the quarter exceeded $30 million- keeping us on track for our 2025 plan. More importantly we executed three different large-scale data center decommission projects with almost no material ending up as scrap. All of the AI-focused enterprise equipment and components recovered from the decommissions were resold at top market value. We head into Q4 with high expectations and our eyes wide open. We’re celebrating the 20-year anniversary of our facility in Hong Kong and looking to add another location in the region to help us process inbound AI data center equipment. Stay tuned for updates. There will be more on the way. View source version on businesswire.com: https://www.businesswire.com/news/home/20251017446548/en/
Avanzanite Bioscience’s Partner Agios Announces Positive CHMP Opinion for PYRUKYND® (mitapivat) for Adults with Thalassemia17.10.2025 14:15:00 CEST | Press release
Avanzanite entered an exclusive partnership with Agios in June 2025 to manage PYRUKYND commercialization across Europe European Commission will now review the CHMP’s opinion, with the final decision expected by early 2026 PYRUKYND is currently approved in Europe for adults with PK deficiency; thalassemia would represent its second indication, pending European Commission approval Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for the new indication for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for t
Kinaxis Accelerates Agentic Era for Supply Chain Orchestration with the Launch of Maestro Agents17.10.2025 13:00:00 CEST | Press release
AI agents that plan with you, not just for you, empower the customer journey to a next generation of the adaptive supply chain Kinaxis® Inc. (TSX: KXS), a global leader in supply chain orchestration, today announced Maestro Agents, marking the next milestone in AI-enabled decision intelligence for supply chains. Now available to Kinaxis customers and embedded natively in Kinaxis Maestro®, these AI-powered context aware digital co-workers help planners move faster from issue to action, turning disruption into opportunity, and strengthening the resilience of the supply chains that power the global economy. “Kinaxis agents are already helping our planning team collaborate more effectively with customers and contract manufacturers,” said John Finnigan, Senior Director, Advanced Planning at Jabil. “With human-in-the-loop safeguards, we’re reaching decisions faster today and see strong potential to build a more resilient and networked supply chain.” Maestro Agents advance the customer journe
SLB Announces Third-Quarter 2025 Results17.10.2025 12:50:00 CEST | Press release
Revenue of $8.93 billion increased 4% sequentially and decreased 3% year on year GAAP EPS of $0.50 decreased 32% sequentially and 40% year on year EPS, excluding charges and credits, of $0.69 decreased 7% sequentially and 22% year on year Net income attributable to SLB of $739 million decreased 27% sequentially and 38% year on year Adjusted EBITDA of $2.06 billion was flat sequentially and decreased 12% year on year Cash flow from operations was $1.68 billion and free cash flow was $1.10 billion, including $153 million of acquisition-related payments Board approved quarterly cash dividend of $0.285 per share SLB (NYSE: SLB) today announced results for the third-quarter 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251015948706/en/ The exterior of the SLB headquarters in Houston, Texas. Third-Quarter Results(Stated in millions, except per share amounts)Three Months EndedChangeSept. 30, 2025Jun. 30, 2025Sept. 30, 2024Se
Dompé's Program in NAION Selected for Landmark FDA Commissioner’s National Priority Voucher Program17.10.2025 02:42:00 CEST | Press release
One of just nine voucher recipients chosen and the only one in the eye space, the selection spotlights Dompé’s dedication to accelerate innovation and deliver breakthrough therapies to patients who urgently need them.With this selection, Dompé receives a voucher shortening the marketing application review from the standard 10–12 months to just 1–2 months.Dompé plans to apply the voucher to its Biologics License Application (BLA) for an intranasal form of Nerve Growth Factor (Cenegermin-bkbj) for the treatment of non-arteritic anterior ischemic optic neuropathy (NAION).Dompé’s intranasal NGF platform builds on the Nobel Prize-winning discovery of neurobiologist Professor Rita Levi-Montalcini and biochemist Dr. Stanley Cohen. Dompé, a leading biopharmaceutical company with operations in Italy and the US, announced today its selection by the United States Food and Drug Administration (FDA) to participate in the Commissioner’s National Priority Voucher (CNPV) program. Because of its select
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom